Real-world efficacy and safety of immunochemotherapy in cold agglutinin-mediated autoimmune haemolytic anaemia
- PMID: 41122858
- DOI: 10.1111/bjh.70215
Real-world efficacy and safety of immunochemotherapy in cold agglutinin-mediated autoimmune haemolytic anaemia
Keywords: autoimmune haemolytic anaemia; bendamustine; cold agglutinin disease; cyclophosphamide; lymphoproliferative.
References
REFERENCES
-
- Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med. 2021;385:1407–1419.
-
- Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136:480–488.
-
- Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648.
-
- Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–1748.
-
- Randen U, Troen G, Tierens A, Steen C, Warsame A, Beiske K, et al. Primary cold agglutinin‐associated lymphoproliferative disease: a B‐cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99:497–504.
Grants and funding
LinkOut - more resources
Full Text Sources
